Skip to content

The HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial

Effectiveness of Rapid HIV Screening Methods in Urban Emergency Departments

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01781949
Acronym
HIV TESTED
Enrollment
76235
Registered
2013-02-01
Start date
2014-04-30
Completion date
2018-08-31
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rapid HIV Screening

Keywords

HIV infection, Targeted screening, Nontargeted screening, Emergency department, Urgent care, Effectiveness

Brief summary

The purpose of this study is to evaluate the effectiveness of 3 modern rapid HIV screening methods, including a novel targeted strategy, in urban emergency department settings in the United States.

Detailed description

Early identification of undiagnosed HIV infection remains a critical public health priority. In the United States, approximately 250,000 HIV-infected individuals remain undiagnosed and 50,000 new infections occur annually, despite several substantial HIV-related public health initiatives. Although HIV testing is an important intervention, controversy still exists as to how it should be implemented. In 2006, the Centers for Disease Control and Prevention (CDC) recommended nontargeted opt-out HIV screening in clinical settings where the undiagnosed prevalence was ≥0.1%. Emergency departments (EDs) have been a major focus of these recommendations, prompted by the fact that over 120 million ED visits occur annually in the United States, they serve large proportions of underserved patients, and are the most common site of missed diagnostic opportunities for HIV infection. In contrast, in 2007 the United States Preventive Services Task Force recommended targeted HIV screening (i.e., testing high-risk subpopulations) as the principal approach to HIV testing because insufficient evidence existed to support the CDC recommendations. Led by Jason Haukoos, MD, MSc, the research team has pioneered investigations in this area since 2004, recently publishing the largest clinical trial to date, concluding that nontargeted opt-out rapid HIV screening in the ED was associated with a small increase in number of newly-identified HIV-infected patients when compared to diagnostic testing (i.e., testing based on clinical signs or symptoms) by physicians. The investigators also recently developed the Denver HIV Risk Score (DHRS), the first multivariable tool to estimate risk of HIV infection. The DHRS combines 3 demographic and 5 behavioral characteristics, and classifies patients into distinct strata with increasing HIV prevalence. To build on this work, the investigators propose the following specific aims: (1) to evaluate and compare the effectiveness of 3 rapid HIV screening strategies when fully-integrated into ED care; (2) to measure and compare programmatic costs of each HIV screening strategy; and (3) to measure and compare ED operational processes of each HIV screening strategy. In doing so, the investigators will perform a multi-center prospective randomized control trial to test the following hypotheses: (1) targeted rapid HIV screening using the DHRS to identify high-risk patients is significantly associated with new HIV diagnoses when compared to traditional targeted rapid HIV screening and nontargeted rapid HIV screening; (2) enhanced and traditional targeted rapid HIV screening is more cost effective per newly-identified patient than nontargeted rapid HIV screening; and (3) enhanced targeted rapid HIV screening is associated with non-inferior ED process metrics and crowding when compared to traditional targeted screening or nontargeted screening. To accomplish these aims, the investigative team will conduct: (1) a prospective randomized controlled pragmatic clinical effectiveness trial in the EDs at Denver Health Medical Center (Denver, CO), Alameda County Medical Center (Oakland, CA), Johns Hopkins Hospital (Baltimore, MD), and the University of Cincinnati Medical Center (Cincinnati, OH); and (2) nested observational studies to evaluate programmatic costs and operational metrics between the 3 rapid HIV screening strategies and using newly-diagnosed HIV infection as the primary outcome.

Interventions

OTHERA: Nontargeted rapid HIV screening

Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.

OTHERB: Enhanced targeted rapid HIV screening

Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS \<30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.

OTHERC: Traditional targeted rapid HIV screening

Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.

Sponsors

Alameda County Medical Center
CollaboratorOTHER
Johns Hopkins University
CollaboratorOTHER
University of Cincinnati
CollaboratorOTHER
Denver Health and Hospital Authority
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Greater than or equal to 16 years of age * Clinically stable * Capable of providing consent for medical care

Exclusion criteria

* \< 16 years old * Unable to consent for medical care * Prisoners or detainees * Self-identified as infected with HIV * Occupational exposure * Sexual assault * Fast-track patients

Design outcomes

Primary

MeasureTime frameDescription
Confirmed Newly-Diagnosed HIV InfectionDay 1Confirmed newly-diagnosed and previously-diagnosed HIV infection; classified as binary yes or no; assessed using structured medical record and laboratory data abstraction.

Secondary

MeasureTime frameDescription
HIV Viral LoadDay 1HIV viral load (copies/mL) at the time of diagnosis; assessed using structured laboratory data abstraction.
Linkage-to-CareExpected average of 1 week, but may be up to 1 monthDetermined by completion of a follow-up linkage-to-care visit within 30 days of initial ED diagnosis; classified as binary yes or no; assessed using structured medical record abstraction.
Development of AIDS1 year after diagnosisUsing conventional definitions for the development of AIDS during any time during the year following diagnosis; classified as binary yes or no; assessed using structured medical record abstraction.
Initiation of Antiretroviral Therapy1 year after diagnosisWhether antiretroviral therapy (ART) was planned or initiated at any time during the year following diagnosis; classified as binary yes or no; assessed using structured medical record abstraction.
CD4 CountDay 1CD4 count (cells/mm3) at the time of diagnosis; assessed using structured laboratory data abstraction.
Hospitalization1 year after diagnosisHospitalization is defined as any unscheduled hospital admission, occurring at any time during the year following diagnosis; measured as binary yes or no and as number of unique hospitalizations; assessed using structured medical record abstraction.
Scheduled Medical Care Visits1 year after diagnosisScheduled medical care visits is defined as all scheduled visits (both outpatient and inpatient), occurring at any time during the year following diagnosis; classified as an interval value of unique visits; assessed using structured medical record abstraction.
Unscheduled Medical Care Visits1 year after diagnosisUnscheduled medical care visits is defined as all unscheduled visits (both outpatient and inpatient), occurring at any time during the year following diagnosis; classified as an interval value of unique visits; assessed using structured medical record abstraction.
Mortality1 year after diagnosisMortality is defined as death at any time during the year following diagnosis; classified as binary yes or no; assessed using structured medical record abstraction.
Treatment for Opportunistic Infections1 year after diagnosisWhether treatment for specific opportunistic infections were initiated at any time during the year following diagnosis; assessed using structured medical record abstraction.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026